View Older Stories View More Recent Stories

Sep 15, 2021 08:30AM PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Sep 13, 2021 08:30AM PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 
Sep 9, 2021 08:30AM PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Sep 7, 2021 08:30AM PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference
Aug 12, 2021 07:05AM PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results
Jul 28, 2021 08:00AM PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences
Jul 26, 2021 08:00AM PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results
Jul 1, 2021 08:30AM PDS Biotechnology Joins Russell Microcap® Index
Jun 17, 2021 04:15PM PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
Jun 14, 2021 08:00AM PDS Biotechnology Announces Oncology Research and Development Day
Jun 8, 2021 07:54AM CORRECTING AND REPLACING -- PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
Jun 8, 2021 06:05AM PDS Biotechnology (PDSB) Highlights Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation
Jun 8, 2021 06:00AM PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
Jun 7, 2021 08:00AM PDS Biotechnology Set to Join Russell Microcap® Index
Jun 3, 2021 08:53AM PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors
Jun 1, 2021 08:27AM PDS Biotech to Host Oncology R&D Day on June 16, 2021
May 27, 2021 07:30AM PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance
May 24, 2021 08:07AM PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting
May 20, 2021 08:10AM PDS Biotechnology (PDSB) Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO
May 20, 2021 08:00AM PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting
May 18, 2021 08:00AM PDS Biotechnology Appoints Immuno-Oncology Experts Dr. Olivera Finn and Dr. Mark Frohlich to Scientific Advisory Board
May 17, 2021 08:00AM PDS Biotech Receives $4.5M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program
May 13, 2021 07:00AM PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results
May 12, 2021 08:00AM PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series
Apr 29, 2021 08:30AM PDS Biotech Announces Oral Presentation of PDS0101 Data by the National Cancer Institute at 2021 American Society of Clinical Oncology Annual Meeting
Apr 26, 2021 04:15PM PDS Biotechnology Announces Conference Call and Webcast for First Quarter Financial Results
Apr 19, 2021 09:22AM PDS Biotech Announces Participation in Noble Capital Markets Virtual Road Show Series
Mar 18, 2021 07:00AM PDS Biotech Reports Financial Results for the Year Ended December 31, 2020 and Provides Business Update
Mar 11, 2021 08:30AM PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercializa
Mar 8, 2021 04:30PM PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2020 Financial Results
Mar 3, 2021 04:30PM PDS Biotech Announces Presentations in Upcoming Healthcare Investor Conferences
Feb 22, 2021 08:30AM PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine
Feb 3, 2021 09:04AM PDS Biotechnology (PDSB) Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Institute
Feb 3, 2021 09:00AM PDS Biotech Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Institute
Jan 14, 2021 08:30AM PDS Biotech Releases White Paper Detailing the Potential of the Versamune® Platform in Overcoming a Major Limitation of Immuno-Oncology
Jan 6, 2021 08:30AM PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan 5, 2021 08:45AM PDS Biotech Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
Dec 21, 2020 08:35AM PDS Biotechnology (PDSB) Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine
Dec 21, 2020 08:30AM PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine
Dec 9, 2020 08:33AM PDS Biotechnology (PDSB) Announces Seth Van Voorhees as CFO
Dec 9, 2020 08:30AM PDS Biotechnology Appoints Seth Van Voorhees as Chief Financial Officer
Nov 16, 2020 08:30AM PDS Biotech Announces New and Broad Versamune® Platform Patent Claims
Nov 13, 2020 03:00PM PDS Biotech to Present at the Virtual Fall Investor Summit on November 16th-18th
Nov 11, 2020 04:05PM PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update
Nov 10, 2020 04:11PM PDS Biotechnology (PDSB) and Farmacore Announce Updates to Co-Development of Versamune-Based COVID-19 Vaccine
Nov 10, 2020 04:05PM PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine
Nov 9, 2020 04:05PM PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Neck Cancer in Collaboration with Merck
Nov 5, 2020 04:05PM PDS Biotechnology Appoints Renowned Oncologist Otis Brawley, M.D. to its Board of Directors
Oct 29, 2020 04:30PM PDS Biotechnology Announces Feature in “Grand Rounds” Webinar hosted by Alliance Global Partners and Conference Call and Webcast for Third Quarter 2020 Financial Results
Oct 26, 2020 08:31AM PDS Biotechnology (PDSB) Commences Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer
View More Recent Stories View Older Stories